Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)
National Institutes of Health (NIH)
Total funding amount: $5.5 million for FY 2026 and FY 2027
Maximum project period: 3 years
To fund studies on type 1 diabetes etiology and pathogenesis using clinical trial data and samples.
To enhance understanding of disease mechanisms leading to improved prevention strategies.
Investigative teams conducting research on type 1 diabetes.
Participants in clinical trials and studies related to type 1 diabetes.
Eligible organization types include higher education institutions, nonprofits, for-profit organizations, local and state governments, and tribal governments.
Non-domestic (non-U.S.) entities are also eligible.
Open to U.S. and non-domestic entities.
Projects must focus on type 1 diabetes research using biosamples and data from clinical studies.
Applications must demonstrate documented access to relevant samples.
Application budgets are limited to $1,200,000 in direct costs per year.
No cost-sharing is required.
Application deadline: March 8, 2026.
Earliest start date for funded projects: June 26, 2025.
No restrictions on prior grant funding mentioned.
Applications must include a letter of support for access to samples.
Compliance with NIH data sharing policies is required.
Applications will be evaluated based on scientific merit, significance, innovation, and feasibility.
Applications will undergo scientific peer review followed by advisory council review.
Scientific and technical merit of the proposed project will be the primary consideration.
Projects must not propose clinical trials.
Research using animal models is not allowed.
Access to samples must comply with NIH policies on data sharing.
Collaboration with existing clinical trial networks is encouraged.
Strong emphasis on collaborative projects may favor larger research teams.
Demonstrating access to high-quality biosamples and data.
Failing to comply with application instructions may lead to rejection.
Engage with consortiums early to secure sample access.
Highlight unique methodologies and collaborative potential in applications.